On June 23, 2008, FDA approved a new Aptivus (tipranavir) oral solution (100 mg/mL). The product label has been updated to include dosing recommendations for pediatric patients 2-18 years of age.

In addition, information regarding oral and parenterally administered midazolam was updated in the Contraindication and Drug Interactions section.

Source: FDA list serve (23 June 2008).
http://www.fda.gov/oashi/aids/listserve/listserve2008.html#062308